STRATA Skin Sciences, Inc. · OTC:SSKN

STRATA Skin Sciences — Investor Presentation (November 2019)

33 slides from STRATA Skin Sciences's investor presentation, Nov 21, 2019

  1. Slide 1: Investor Presentation November 2019

    Investor Presentation November 2019 Driving Value to Dermatology Partners Matching Patients with Clinics © 2019 copyright Strata® Skin Sciences NASDAQ: SSKN

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be de

  3. Slide 3: STRATA Investment Highlights

    STRATA Investment Highlights A Win-Win-Win CompanyFor patients – safest, most effective, no side effectsFor clinics – stable increased revenue baseFor Payers – the least expensive treatment availableExcimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Atopic Dermatitis and Leukod

  4. Slide 4: How XTRAC Works - Psoriasis

    How XTRAC Works - Psoriasis 4 After 4 tx After 2 tx Baseline Beam of UVB light applied to the affected area UVB light induces apoptosis of the keratinocytes and T cells in the dermis Promotes immunosuppression Induces alterations in cytokine profile 150+ peer reviewed published clinical studies PASI

  5. Slide 5: How XTRAC Works - Vitiligo

    How XTRAC Works - Vitiligo Long-term skin condition characterized by patches of skin losing its pigment Disease is believed to be due to genetic susceptibility where the autoimmune disease is then triggeredPotentially the immune system is attacking and destroying melanocytes of the skinLife-altering

  6. Slide 6: XTRAC a True Partnership: A complete business solution

    XTRAC a True Partnership: A complete business solution Clinical Support Reimbursement Support Call Center Support Field Service Support Consumables and Parts Laser Upgrades Co-pay Support DTC Marketing 6

  7. Slide 7: Domestic XTRAC Revenue Funnel

    Domestic XTRAC Revenue Funnel 7 REOCCURRENCE DTC ADVERTISING ASSIGNING A DOCTOR PARTNER PATIENTAPPOINTMENT TREATMENT WIN WIN WIN DOCTOR PATIENT STRATA (AND PAYER) INTEREST CREATION IN-HOUSE CALL CENTER INSURANCE ADVOCACY VERIFY APPOINTMENTPrescription of treatment VERIFY XTRACTREATMENT Patient leads

  8. Slide 8: XTRAC helps patients Live Clear, Live Free

    XTRAC helps patients Live Clear, Live Free… https://youtu.be/GdMBliZYy70 8

  9. Slide 9: 50,000 People See XTRAC Ads Daily

    50,000 People See XTRAC Ads Daily 9

  10. Slide 10: Insurance coverage and new patient growth

    193% of Psoriasis and 63% of Vitiligo patients have XTRAC as a covered insurance benefit 2New Patients captured in STRATA reimbursement system. 30%  30% new patient growth YTD 2019; 86% covered by insurance1 10

  11. Slide 11: STRATA's Revenue Model

    STRATA’s Revenue Model 11 + 38 devices 26% growth 3% Growth 13% Growth 1Reflects only partners that purchase treatment codes on an as needed basis. Other partners purchase codes on a fixed monthly billing. 2Revenue is net of discounts and co-pay support As of September 30, 2018 and September 30, 201

  12. Slide 12: Growth of XTRAC Share in PE Groups

    Growth of XTRAC Share in PE Groups Combination of new XTRAC placements and PE Clinic acquisitions Install Base Growth Drivers 12 1,658 clinics owned by 58 roll-up groups182 (11%) of which are XTRAC partnersStrata signed strategic expansion agreements with major groups Expansion into PE group clinic

  13. Slide 13: Domestic Market: Installed Base

    Domestic Market: Installed Base – sales and service engine 13 Territories color coded Overview784 Partner XTRAC clinics150+ sold XTRAC4 Regions26 Sales Territories15 Field Service TechsIn-house call center to qualify leadsOnly one competitor in U.S.

  14. Slide 14: Partner Academic Institutions

    Partner Academic Institutions 14

  15. Slide 15: International Market: Installed Base

    International Market: Installed Base Strategic Growth TargetsMajor Markets – China, Japan, Saudi Arabia, South KoreaInsurance covered in most marketsUsage/device higher than domestic market – untapped potential in U.S.1,300 OUS devices sold and in servicePlacement recurring revenue model agreement e

  16. Slide 16: Financial Metrics - recurring revenue and margin growth

    Financial Metrics – recurring revenue and margin growth 16 Note: all quarterly numbers are unaudited Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q1 2019 Q2 2019 Q3 2019 Dermatology recurring revenue $4,770 $5,022 $5,393 $5,868 $5,312 $5,839 $5,991 Dermatology equipment revenue $1,968 $2,366 $2,336 $2,132 $2,171

  17. Slide 17: Financial Profile: Shares and Share Equivalents

    (As of November 14, 2019) * On an as converted basis of the convertible preferred stock** Does not include 750K warrants with a weighted average exercise price of $4.12 as of September 30, 2019 of which 600K expire by June 2020** Does not include 4.0M options with a weighted average exercise price o

  18. Slide 18: STRATA Investment Highlights

    STRATA Investment Highlights A Win-Win-Win CompanyFor patients – safest, most effective, no side effectsFor clinics – stable increased revenue baseFor Payers – the least expensive treatment availableExcimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Atopic Dermatitis and Leukod

  19. Slide 19: Driving Value to Dermatology Partners

    Investor Presentation November 2019 Driving Value to Dermatology Partners Matching Patients with Clinics © 2019 copyright Strata® Skin Sciences NASDAQ: SSKN

  20. Slide 20: Appendix

    Appendix 20

  21. Slide 21: Additional Creative

    Additional Creative STRATA

  22. Slide 22: XTRAC Excimer laser is FDA cleared

    XTRAC® Excimer laser is FDA cleared for Psoriasis, Vitiligo, Atopic Dermatitis and Leukoderma. It uses a highly targeted beam of 308nm UVB to treat affected skin without damaging surrounding healthy tissue. Treatment has minimal side effects, avoids messy topicals and high cost of biologics. #1 Pres

  23. Slide 23: Continuous technology investment and business growth

    Continuous technology investment and business growth 23 510 (K) FDA Approval AL-7000 Ultra Velocity 400 Velocity 700 Velocity 7 Series S3 2000 2005 2008 2010 2014 2018 CPT code Approval DTC platform creation 510 (K) FDA Approval (MMD)* Full Insurance Reimbursement 2012 *MMD tip is a diagnostic acces

  24. Slide 24: Historical phototherapy utilization

    24 Historical phototherapy utilization. Trend in phototherapy utilization among Medicare beneficiaries by billing code across all providers, 2000 to 2015. HCPCS, Healthcare Common Procedure Coding System; PUVA, psoralen plus ultraviolet A; UVB, ultraviolet B. 30% 30% annual growth in excimer laser u

  25. Slide 25: Sample studies from 150+ clinical studies

    Multicenter Psoriasis Study1 Scalp Study3 124 patients were enrolled and 80 completed the protocol. 72% achieved at least 75% clearing in an average of 6.2 treatments. 84% of patients reached improvement of 75% or better after 10 or fewer treatments. 50% of patients reached improvement of 90% or bet

  26. Slide 26: Maximizing Dermatologist Partner Clinical Revenue

    Maximizing Dermatologist Partner Clinical Revenue 26 Data collected directly from the lasers demonstrates the importance of following treatment guidelines Revenue = # of lasers x # of treatments/pt x # patients x cost/tx x recurrence factor

  27. Slide 27: XTRAC a preferred treatment for 90% of psoriasis patients

    Source: National Psoriasis Foundation American Academy of Dermatology Psoriasis Clinical Guideline XTRAC a preferred treatment for 90% of psoriasis patients (<10% BSA) 27

  28. Slide 28: Opportunity map for XTRAC Indications

    Opportunity map for XTRAC Indications Number of Strata Patients* Prevalence Source Atopic dermatitis 1,200 18 Million National Eczema Association Vitiligo 9,000 2-5 Million Vitiligo Support Psoriasis 18,000 7.5 Million NPF Topicals/ Targeted Phototherapy Systemics/Biologics/UVB Booth Recommended Act

  29. Slide 29: Phototherapy has highest patient perceived treatment effectiveness

    Source: Findings From the National Psoriasis Foundation Surveys, 2003-2011 (n=5604) Source: Real-world health outcomes study sponsored by Eli Lilly (n=2200) Phototherapy has highest patient perceived treatment effectiveness 29

  30. Slide 30: Leads, Appointments, RDX Charts

    Leads, Appointments, RDX Charts YTD Dec 2015 YTD Dec 2016 YTD Dec 2017 YTD Dec 2018 YTD Sep 2018 YTD Sep 2019 Leads 36,473 21,296 7,269 22,213 13,485 37,701 Appointments 10,032 6,524 2,563 3,856 2,536 4,711 RDX Charts 26,237 23,481 18,747 18,105 13,162 17,181 30

  31. Slide 31: Total Calls in call center

    Total Calls in call center 250,000 200,000 150,000 100,000 STRATA 125,449 YTD Dec 2015, 140,902 YTD Dec 2016 67,129 YTD Dec 2017 Total Calls 208,054 YTD Dec 2018 198,339 99,592 a

  32. Slide 32: XTRAC adds recurring revenue driver for its partners

    XTRAC adds (delegated) recurring revenue driver for its partners Treatment Patient Type Reimbursement Details Annual Revenue per Patient Can be delegated** XTRAC Mild / moderate / severe CPT Code 96920-96922 ($168-$251) average $186; 16 tx/course (2/yr) and Office Visit -$70 (2/Yr) $6,092  Photothe

  33. Slide 33: How XTRAC works for offices

    How XTRAC works for offices: $250 revenue in less than 7 minutes *Subjected to state regulation Established CPT Codes 2019 National Medicare Average Rate 96920 - $167.2296921 - $183.4496922 - $249.03 33

STRATA Skin Sciences — Investor Presentation (November 2019) on 6ix